Table 2 Distribution of inhibitory molecules on CD4+ and CD8+ T cells in BM aspirates and PB of myeloma patients and healthy persons
From: T cells in multiple myeloma display features of exhaustion and senescence at the tumor site
BM | PB | |||||
|---|---|---|---|---|---|---|
Healthy Median % (IQR) | Myeloma Median % (IQR) | Healthy Median % (IQR) | Myeloma Median % (IQR) | |||
CD4+ T cells | ||||||
PD-1+ | 44.4 (17.7–60.3) | 64.5 (36.8–77.4) | * | 47.2 (21.6–60.2) | 66.6 (48.0–74.8) | * |
2B4+ | 30.3 (7.3–43.2) | 36.1 (28.4–47.3) | n.s. | 33.7 (17.8–45.2) | 33.4 (19.1–44.6) | n.s. |
CD160+ | 29.4 (8.3–33.2) | 30.8 (23.4–39.0) | n.s. | 33.1 (10.5–37.3) | 30.6 (16.8–38.9) | n.s. |
CTLA-4+ | 43.5 (29.4–56.6) | 60.3 (52.2–64.4) | * | 48.8 (37.9–59.6) | 56.7 (35.6–65.4) | n.s. |
CD8+ T cells | ||||||
PD-1+ | 60.7 (50.8–69.4) | 73.0 (65.7–86.8) | * | 50.20 (42.0–66.7) | 74.1 (57.8–81.9) | * |
2B4+ | 42.0 (24.1–46.1) | 58.5 (43.1–69.0) | * | 56.50 (36.7–69.6) | 59.4 (49.3–70.3) | n.s. |
CD160+ | 38.7 (22.9–49.8) | 56.4 (44.4–64.8) | * | 44.30 (16.6–57.8) | 49.4 (40.5–59.2) | n.s. |
CTLA-4+ | 53.1 (44.9–59.6) | 65.8 (61.9–67.9) | ** | 58.55 (43.5–64.2) | 64.7 (60.6–71.8) | n.s. |